Loading...
•
Mar 31
Precision BioSciences Q1 2025 Earnings Report
Precision BioSciences reported a significant net loss in Q1 2025 amid strategic focus on key gene editing programs.
Key Takeaways
Precision BioSciences posted minimal revenue for Q1 2025 while advancing its lead in vivo gene editing programs. The company reported a net loss of $20.6 million and emphasized its strong cash position and progress in clinical trials for PBGENE-HBV and PBGENE-DMD.
Q1 2025 revenue was under $0.1 million, down from $17.6 million in Q1 2024.
Net loss for the quarter was $20.6 million, or $2.21 per share.
Precision reported cash, cash equivalents, and restricted cash of $99.8 million.
The company had over 10.5 million shares outstanding as of March 31, 2025.
Precision BioSciences
Precision BioSciences
Forward Guidance
Precision plans to advance PBGENE-HBV and PBGENE-DMD programs through Phase 1 data readouts with a cash runway expected into H2 2026.
Positive Outlook
- Encouraging safety data for PBGENE-HBV from ELIMINATE-B trial
- PBGENE-HBV granted Fast Track Designation by FDA
- PBGENE-DMD showed sustained functional improvements in preclinical models
- Regulatory approvals received to expand HBV trial in US and UK
- Cash runway expected to support operations through H2 2026
Challenges Ahead
- Sharp revenue decline due to end of legacy collaboration agreements
- Operating loss of over $22 million for the quarter
- Paused development of PBGENE-3243 due to prioritization of other programs
- Minimal external revenue contributions expected near term
- Continued high R&D spending necessary to support pipeline progression